<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>treatment on Covid Papers</title>
    <link>http://covidpapers.github.io/categories/treatment/</link>
    <description>Recent content in treatment on Covid Papers</description>
    <generator>Hugo -- gohugo.io</generator>
    <lastBuildDate>Fri, 10 Apr 2020 15:33:50 -0500</lastBuildDate>
    
	<atom:link href="http://covidpapers.github.io/categories/treatment/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Some encouraging results from Remdesivir study just released</title>
      <link>http://covidpapers.github.io/posts/compassionate-use-of-remdesivir-for-patients-with-severe-covid-19/</link>
      <pubDate>Fri, 10 Apr 2020 15:33:50 -0500</pubDate>
      
      <guid>http://covidpapers.github.io/posts/compassionate-use-of-remdesivir-for-patients-with-severe-covid-19/</guid>
      <description>Just published in the NEJM.
Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in very sick patients on mechanical ventilation with 18% fatality (only, expect &amp;gt; 50%) and overall 68% improvement https://t.co/oP8eDK6jYL @NEJM pic.twitter.com/9kisPxy1un
&amp;mdash; Eric Topol (@EricTopol) April 10, 2020  Key findings
 53 patients 17 of 30 patients on ventilation were extubated 3 or 4 patients on ECMO stopped receiving it &amp;ldquo;clinical improvement was observed in 36 of 53 patients (68%)&amp;rdquo; 25 of 53 were discharged 7 of 53 died rates of adverse events were high at 60%, 23% of which were serious  Study participants were given a 10-day course of Remdesivir: an IV loading dose of 200mg and 100mg daily the following 9 days.</description>
    </item>
    
    <item>
      <title>Whats the Deal with Hydroxychloroquine? The current state of scientific knowledge.</title>
      <link>http://covidpapers.github.io/posts/whats-the-deal-with-hydroxychloroquine/</link>
      <pubDate>Sun, 05 Apr 2020 23:53:32 -0500</pubDate>
      
      <guid>http://covidpapers.github.io/posts/whats-the-deal-with-hydroxychloroquine/</guid>
      <description>Let&amp;rsquo;s take a quick look at what the science says today about Hydroxychloroquine or HCQ.
A recent letter in the Annals of Internal Medicine offers a TL;DR
 Data to support the use of HCQ and CQ for COVID-19 are limited and inconclusive.
 The French Study If you&amp;rsquo;ve heard anything at all about HCQ, it&amp;rsquo;s probably in some way related to this French study which came out without peer review in mid March.</description>
    </item>
    
  </channel>
</rss>